Clinical Trials · NCT00240253

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Name: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Pramlintide

Phase: Phase 4
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 200
Start date: Oct 2005
Locations: 34 sites, United States
Primary endpoint: To evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes.

View Pramlintide compound reference